ストックスクリーナーアプリを入手
0.8859
5.09%
0.0429
アフターアワーズ：
.91
0.0241
+2.72%
前日終値:
$0.843
開ける：
$0.8231
24時間の取引高:
743.65K
Relative Volume:
1.01
時価総額：
$84.58M
収益：
$169.43M
当期純損益:
$-186.01M
株価収益率:
0.5986
EPS:
1.48
ネットキャッシュフロー:
$70.07M
1週間 パフォーマンス:
-3.71%
1か月 パフォーマンス:
-6.75%
6か月 パフォーマンス:
-23.63%
1年 パフォーマンス:
-14.82%
1日の値動き範囲:
$0.81
$0.9091
1週間の範囲:
$0.81
$0.96
52週間の値動き範囲:
$0.7324
$1.798
Assertio Holdings Inc Stock (ASRT) Company Profile
名前
Assertio Holdings Inc
セクター
電話
(224) 419-7106
住所
100 S. SAUNDERS ROAD, LAKE FOREST, IL
ASRT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ASRT
Assertio Holdings Inc
|
0.8859 | 84.58M | 169.43M | -186.01M | 70.07M | -2.02 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Assertio Holdings Inc Stock (ASRT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-26 | 開始されました | Maxim Group | Buy |
| 2024-07-03 | 開始されました | H.C. Wainwright | Buy |
| 2022-11-07 | 開始されました | Lake Street | Buy |
| 2018-11-30 | ダウングレード | Mizuho | Buy → Neutral |
Assertio Holdings Inc (ASRT) 最新ニュース
Assertio appoints new independent director to board By Investing.com - Investing.com South Africa
Assertio appoints new independent director to board - Investing.com
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - The Manila Times
Assertio Holdings Taps Former Astellas President Who Led $5B Sales Growth to Join Board - StockTitan
Assertio’s (ASRT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Assertio Therapeutics shares get buy rating on clinical trial results By Investing.com - Investing.com Canada
Assertio (NASDAQ:ASRT) Receives Buy Rating from HC Wainwright - MarketBeat
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Down 11.5% in November - MarketBeat
Assertio reports positive Rolvedon trial results for breast cancer By Investing.com - Investing.com Australia
Assertio Announces Results of Rolvedon (Eflapegrastim-Xnst) Injection Same-Day Dosing Clinical Study - Marketscreener.com
Assertio reports positive Rolvedon trial results for breast cancer - Investing.com
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - The Manila Times
Assertio's Rolvedon Shows Promising Clinical Data in Breast Cancer Trial with Same-Day Chemo Dosing - StockTitan
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO - The Manila Times
Assertio Holdings Creates Transformation Office, Appoints New Leadership to Drive Growth Strategy - StockTitan
Assertio Holdings Inc (NASDAQ: ASRT): Blank Check On Growth? - Stocks Register
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - GlobeNewswire Inc.
Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com
HC Wainwright Forecasts Stronger Earnings for Assertio - MarketBeat
Assertio shares hold price target, buy rating on stable Indocin share By Investing.com - Investing.com Canada
Assertio Holdings Q3 2024 Earnings Preview - MSN
Assertio stock gains amid Q3 earnings, clash with activist investor - MSN
Insider Buying: Assertio Holdings, Inc. (NASDAQ:ASRT) Director Acquires $60,000.00 in Stock - MarketBeat
Assertio Holdings director Heather Mason buys $60,000 in shares By Investing.com - Investing.com Nigeria
Assertio Holdings director Heather Mason buys $60,000 in shares - Investing.com
Assertio Holdings CEO Brendan O'Grady buys $9,950 in common stock - Investing.com India
Spectrum Pharma Faces Senate Probe Call Over Alleged Rolvedon Data Fraud | ASRT Stock News - StockTitan
Assertio Holdings Inc (ASRT) Quarterly 10-Q Report - Quartz
Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2024 Earnings Call Transcript - Insider Monkey
Assertio: Q3 Earnings Snapshot - The Washington Post
Assertio Therapeutics’ Q3 2024 Earnings Overview - TipRanks
Assertio stock gains amid Q3 earnings, clash with activist investor (NASDAQ:ASRT) - Seeking Alpha
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Assertio Reports Third Quarter 2024 Financial Results - The Manila Times
Assertio Holdings, Inc. Announces Board Changes - Marketscreener.com
Assertio Holdings Faces SEC Whistleblower Complaint Over Alleged Clinical Data Fraud | ASRT Stock News - StockTitan
Assertio Provides Response to Letter from Short-seller - GlobeNewswire
Assertio Holdings CEO Fires Back at Short-Seller's 'Baseless' Rolvedon Claims | ASRT Stock News - StockTitan
Assertio Holdings (NASDAQ:ASRT investor five-year losses grow to 72% as the stock sheds US$17m this past week - Simply Wall St
Assertio faces fraud claims, investor goes short on stock By Investing.com - Investing.com India
Assertio Stock Alert: Major Investor Warns of Fraud Claims, Safety Issues in Spectrum Deal | ASRT Stock News - StockTitan
Assertio Holdings Inc (ASRT) Q3 2024: Everything You Need to Know Ahead of Earnings - Yahoo Finance
Sidoti Csr Issues Negative Forecast for Assertio Earnings - MarketBeat
Assertio (ASRT) Scheduled to Post Earnings on Monday - MarketBeat
ASRTAssertio Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024 - The Manila Times
Non-Steroidal Anti-Inflammatory Drugs Market Sees Robust Growth Amid Rising Demand | PLC, and Assertio - EIN News
Director Vacirca Jeff L acquire 10,000 shares of Assertio Holdings Inc [ASRT] - Knox Daily
Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024 - GlobeNewswire
Assertio Holdings Inc (ASRT) 財務データ
収益
当期純利益
現金流量
EPS
Assertio Holdings Inc (ASRT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| O'Grady Brendan P. | CEO |
Nov 14 '24 |
Buy |
0.85 |
11,706 |
9,950 |
11,706 |
| Schlessinger Sam | SVP, General Counsel |
Oct 01 '24 |
Option Exercise |
0.00 |
19,404 |
0 |
141,459 |
| Vacirca Jeff L | Director |
Jun 11 '24 |
Buy |
1.11 |
10,000 |
11,100 |
151,159 |
| Mason Heather L | Interim Executive Officer |
Jun 05 '24 |
Buy |
0.97 |
25,000 |
24,250 |
212,650 |
| Schlessinger Sam | SVP, General Counsel |
May 12 '24 |
Option Exercise |
0.00 |
38,017 |
0 |
138,895 |
| Schwichtenberg Paul | SVP, CCO |
May 12 '24 |
Option Exercise |
0.00 |
38,017 |
0 |
141,941 |
| Patel Ajay | SVP and CFO |
May 12 '24 |
Option Exercise |
0.00 |
38,017 |
0 |
171,271 |
| Tyree James L | Director |
Mar 14 '24 |
Sale |
1.12 |
10,251 |
11,463 |
188,251 |
| Schlessinger Sam | SVP, General Counsel |
Feb 21 '24 |
Option Exercise |
0.00 |
17,151 |
0 |
109,384 |
| Schwichtenberg Paul | SVP, CCO |
Feb 21 '24 |
Option Exercise |
0.00 |
17,151 |
0 |
112,430 |
1.61%
1.65%
大文字化:
|
ボリューム (24 時間):